Am J Perinatol 2023; 40(09): 1026-1032
DOI: 10.1055/s-0043-1761915
PAS Series Article
Review Article

General Management Considerations for Placenta Accreta Spectrum

Brett D. Einerson
1   University of Utah Health, Salt Lake City, Utah
,
Adam T. Sandlin
2   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, Arizona
,
Yalda Afshar
3   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, California
,
Nadir Sharawi
4   Department of Anesthesiology, University of Arkansas for Medical Sciences, Little Rock, Arizona
,
Karin A. Fox
5   Division of Maternal-Fetal Medicine, Department of Obstetric and Gynecology, Baylor College of Medicine (Texas Children's Hospital Pavilion for Women), Houston, Texas
,
J. M. Newton
6   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center Nashville, Tennessee
,
Scott A. Shainker
7   Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
,
Amir Pezeshkmehr
8   Department of Radiology Texas Children's Hospital/Baylor College of Medicine, Houston, Texas
,
Daniela A. Carusi
9   Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
,
Leslie Moroz
10   Yale School of Medicine, New Haven, Connecticut
› Institutsangaben

Abstract

The ideal management of a patient with placenta accreta spectrum (PAS) includes close antepartum management culminating in a planned and coordinated delivery by an experienced multidisciplinary PAS team. Coordinated team management has been shown to optimize outcomes for mother and infant. This section provides a consensus overview from the Pan-American Society for the Placenta Accreta Spectrum regarding general management of PAS.



Publikationsverlauf

Artikel online veröffentlicht:
19. Juni 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. Incidence and risk factors for placenta accreta/increta/percreta in the UK: a national case-control study. PLoS One 2012; 7 (12) e52893
  • 2 Bailit JL, Grobman WA, Rice MM. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol 2015; 125 (03) 683-689
  • 3 Silver RM, Fox KA, Barton JR. et al. Center of excellence for placenta accreta. Am J Obstet Gynecol 2015; 212 (05) 561-568
  • 4 Shamshirsaz AA, Fox KA, Salmanian B. et al. Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach. Am J Obstet Gynecol 2015; 212 (02) 218.e1-218.e9
  • 5 Shamshirsaz AA, Fox KA, Erfani H. et al. Multidisciplinary team learning in the management of the morbidly adherent placenta: outcome improvements over time. Am J Obstet Gynecol 2017; 216 (06) 612.e1-612.e5
  • 6 Shamshirsaz AA, Fox KA, Erfani H. et al. Outcomes of planned compared with urgent deliveries using a multidisciplinary team approach for morbidly adherent placenta. Obstet Gynecol 2018; 131 (02) 234-241
  • 7 Ruiter L, Eschbach SJ, Burgers M. et al. Predictors for emergency cesarean delivery in women with placenta previa. Am J Perinatol 2016; 33 (14) 1407-1414
  • 8 Pivano A, Alessandrini M, Desbriere R. et al. A score to predict the risk of emergency caesarean delivery in women with antepartum bleeding and placenta praevia. Eur J Obstet Gynecol Reprod Biol 2015; 195: 173-176
  • 9 American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta accreta spectrum. Obstet Gynecol 2018; 132: e259-e275
  • 10 Silver RM. Abnormal placentation: placenta previa, vasa previa, and placenta accreta. Obstet Gynecol 2015; 126 (03) 654-668
  • 11 Miller ES, Grobman WA, Fonseca L, Robinson BK. Indomethacin and antibiotics in examination-indicated cerclage: a randomized controlled trial. Obstet Gynecol 2014; 123 (06) 1311-1316
  • 12 Warshak CR, Ramos GA, Eskander R. et al. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. Obstet Gynecol 2010; 115 (01) 65-69
  • 13 Rac MWF, Wells CE, Twickler DM, Moschos E, McIntire DD, Dashe JS. Placenta accreta and vaginal bleeding according to gestational age at delivery. Obstet Gynecol 2015; 125 (04) 808-813
  • 14 Perlman NC, Little SE, Thomas A, Cantonwine DE, Carusi DA. Patient selection for later delivery timing with suspected previa-accreta. Acta Obstet Gynecol Scand 2017; 96 (08) 1021-1028
  • 15 Collins SL, Alemdar B, van Beekhuizen HJ. et al; International Society for Abnormally Invasive Placenta (IS-AIP). Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol 2019; 220 (06) 511-526
  • 16 Erfani H, Fox KA, Clark SL. et al. Maternal outcomes in unexpected placenta accreta spectrum disorders: single-center experience with a multidisciplinary team. Am J Obstet Gynecol 2019; 221 (04) 337.e1-337.e5
  • 17 Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet 2019; 146 (01) 20-24
  • 18 Kidney DD, Nguyen AM, Ahdoot D, Bickmore D, Deutsch LS, Majors C. Prophylactic perioperative hypogastric artery balloon occlusion in abnormal placentation. AJR Am J Roentgenol 2001; 176 (06) 1521-1524
  • 19 Tan CH, Tay KH, Sheah K. et al. Perioperative endovascular internal iliac artery occlusion balloon placement in management of placenta accreta. AJR Am J Roentgenol 2007; 189 (05) 1158-1163
  • 20 Carnevale FC, Kondo MM, de Oliveira Sousa Jr W. et al. Perioperative temporary occlusion of the internal iliac arteries as prophylaxis in cesarean section at risk of hemorrhage in placenta accreta. Cardiovasc Intervent Radiol 2011; 34 (04) 758-764
  • 21 Cali G, Forlani F, Giambanco L. et al. Prophylactic use of intravascular balloon catheters in women with placenta accreta, increta and percreta. Eur J Obstet Gynecol Reprod Biol 2014; 179: 36-41
  • 22 Russo RM, Girda E, Kennedy V, Humphries MD. Two lives, one REBOA: hemorrhage control for urgent cesarean hysterectomy in a Jehovah's Witness with placenta percreta. J Trauma Acute Care Surg 2017; 83 (03) 551-553
  • 23 Manzano-Nunez R, Escobar-Vidarte MF, Naranjo MP. et al. Expanding the field of acute care surgery: a systematic review of the use of resuscitative endovascular balloon occlusion of the aorta (REBOA) in cases of morbidly adherent placenta. Eur J Trauma Emerg Surg 2018; 44 (04) 519-526
  • 24 Ordoñez CA, Manzano-Nunez R, Parra MW. et al. Prophylactic use of resuscitative endovascular balloon occlusion of the aorta in women with abnormal placentation: A systematic review, meta-analysis, and case series. J Trauma Acute Care Surg 2018; 84 (05) 809-818
  • 25 Picel AC, Wolford B, Cochran RL, Ramos GA, Roberts AC. Prophylactic internal iliac artery occlusion balloon placement to reduce operative blood loss in patients with invasive placenta. J Vasc Interv Radiol 2018; 29 (02) 219-224
  • 26 Bodner LJ, Nosher JL, Gribbin C, Siegel RL, Beale S, Scorza W. Balloon-assisted occlusion of the internal iliac arteries in patients with placenta accreta/percreta. Cardiovasc Intervent Radiol 2006; 29 (03) 354-361
  • 27 Shrivastava V, Nageotte M, Major C, Haydon M, Wing D. Case-control comparison of cesarean hysterectomy with and without prophylactic placement of intravascular balloon catheters for placenta accreta. Am J Obstet Gynecol 2007; 197 (04) 402.e1-402.e5
  • 28 Blumenthal E, Rao R, Murphy A. et al. Pilot study of intra-aortic balloon occlusion to limit morbidity in patients with adherent placentation undergoing cesarean hysterectomy. AJP Rep 2018; 8 (02) e57-e63
  • 29 Bishop S, Butler K, Monaghan S, Chan K, Murphy G, Edozien L. Multiple complications following the use of prophylactic internal iliac artery balloon catheterisation in a patient with placenta percreta. Int J Obstet Anesth 2011; 20 (01) 70-73
  • 30 Wei X, Zhang J, Chu Q. et al. Prophylactic abdominal aorta balloon occlusion during caesarean section: a retrospective case series. Int J Obstet Anesth 2016; 27: 3-8
  • 31 Zhang N, Lou WH, Zhang XB. et al. Vascular complications following prophylactic balloon occlusion of the internal iliac arteries resolved by successful interventional thrombolysis in a patient with morbidly adherent placenta. J Zhejiang Univ Sci B 2017; 18 (03) 272-276
  • 32 Whittington JR, Pagan ME, Nevil BD. et al. Risk of vascular complications in prophylactic compared to emergent resuscitative endovascular balloon occlusion of the aorta (REBOA) in the management of placenta accreta spectrum. J Matern Fetal Neonatal Med 2022; 35 (16) 3049-3052
  • 33 Eller AG, Porter TF, Soisson P, Silver RM. Optimal management strategies for placenta accreta. BJOG 2009; 116 (05) 648-654
  • 34 Matsubara S, Kuwata T, Usui R. et al. Important surgical measures and techniques at cesarean hysterectomy for placenta previa accreta. Acta Obstet Gynecol Scand 2013; 92 (04) 372-377
  • 35 Crocetto F, Esposito R, Saccone G. et al. Use of routine ureteral stents in cesarean hysterectomy for placenta accreta. J Matern Fetal Neonatal Med 2021; 34 (03) 386-389
  • 36 Tam Tam KB, Dozier J, Martin Jr JN. Approaches to reduce urinary tract injury during management of placenta accreta, increta, and percreta: a systematic review. J Matern Fetal Neonatal Med 2012; 25 (04) 329-334
  • 37 Fratto VM, Conturie CL, Ballas J. et al; University of California fetal Consortium. Assessing the multidisciplinary team approaches to placenta accreta spectrum across five institutions within the University of California fetal Consortium (UCfC). J Matern Fetal Neonatal Med 2021; 34 (18) 2971-29766
  • 38 Fox KA, Shamshirsaz AA, Carusi D. et al. Conservative management of morbidly adherent placenta: expert review. Am J Obstet Gynecol 2015; 213 (06) 755-760
  • 39 Pan Y, Zhou X, Yang Z, Cui S, De W, Sun L. Retrospective cohort study of prophylactic intraoperative uterine artery embolization for abnormally invasive placenta. Int J Gynaecol Obstet 2017; 137 (01) 45-50
  • 40 Lee PS, Kempner S, Miller M. et al. Multidisciplinary approach to manage antenatally suspected placenta percreta: updated algorithm and patient outcomes. Gynecol Oncol Res Pract 2017; 4: 11
  • 41 Zuckerwise LC, Bennett KA, Newton JM, Crispens MA. The optimal approach to surgical management of severe placenta accreta spectrum remains unclarified: a call to action. Am J Obstet Gynecol 2020; 223 (02) 305
  • 42 Zuckerwise LC, Craig AM, Newton JM, Zhao S, Bennett KA, Crispens MA. Outcomes following a clinical algorithm allowing for delayed hysterectomy in the management of severe placenta accreta spectrum. Am J Obstet Gynecol 2020; 222 (02) 179.e1-179.e9
  • 43 Sentilhes L, Kayem G, Chandraharan E, Palacios-Jaraquemada J, Jauniaux E. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Conservative management. Int J Gynaecol Obstet 2018; 140 (03) 291-298
  • 44 Sentilhes L, Ambroselli C, Kayem G. et al. Maternal outcome after conservative treatment of placenta accreta. Obstet Gynecol 2010; 115 (03) 526-534
  • 45 Clausen C, Lönn L, Langhoff-Roos J. Management of placenta percreta: a review of published cases. Acta Obstet Gynecol Scand 2014; 93 (02) 138-143
  • 46 Roulot A, Barranger E, Morel O, Soyer P, Héquet D. [Two- and three-dimensional power Doppler ultrasound in the follow-up of placenta accreta treated conservatively]. J Gynecol Obstet Biol Reprod (Paris) 2015; 44 (02) 176-183
  • 47 Sentilhes L, Seco A, Azria E, Beucher G, Bonnet MP, Branger B, Carbillon L, Chiesa C, Crenn-Hebert C, Dreyfus M, Dupont C, Fresson J, Huissoud C, Langer B, Morel O, Patrier S, Perrotin F, Raynal P, Rozenberg P, Rudigoz RC, Vendittelli F, Winer N, Deneux-Tharaux C, Kayem G. PACCRETA Study Group. Conservative management or cesarean hysterectomy for placenta accreta spectrum: the PACCRETA prospective study. Am J Obstet Gynecol 2022; 226 (06) 839.e1-839-e24
  • 48 Palacios-Jaraquemada J. Uterus-conserving surgery: tactics to avoid bleeding in placenta percreta. BJOG 2008; 115 (13) 1717-1718 , author reply 1718
  • 49 Palacios-Jaraquemada JM, Fiorillo A, Hamer J, Martínez M, Bruno C. Placenta accreta spectrum: a hysterectomy can be prevented in almost 80% of cases using a resective-reconstructive technique. J Matern Fetal Neonatal Med 2022; 35 (02) 275-282
  • 50 Chandraharan E, Rao S, Belli AM, Arulkumaran S. The Triple-P procedure as a conservative surgical alternative to peripartum hysterectomy for placenta percreta. Int J Gynaecol Obstet 2012; 117 (02) 191-194
  • 51 Pinas-Carrillo A, Bhide A, Moore J. et al. Outcomes of the first 50 patients with abnormally invasive placenta managed using the “Triple P Procedure” conservative surgical approach. Int J Gynaecol Obstet 2020; 148 (01) 65-71
  • 52 Kayem G, Davy C, Goffinet F, Thomas C, Clément D, Cabrol D. Conservative versus extirpative management in cases of placenta accreta. Obstet Gynecol 2004; 104 (03) 531-536
  • 53 Ganguli S, Faintuch S, Salazar GM, Rabkin DJ. Postembolization syndrome: changes in white blood cell counts immediately after uterine artery embolization. J Vasc Interv Radiol 2008; 19 (03) 443-445
  • 54 Legendre G, Zoulovits FJ, Kinn J, Senthiles L, Fernandez H. Conservative management of placenta accreta: hysteroscopic resection of retained tissues. J Minim Invasive Gynecol 2014; 21 (05) 910-913
  • 55 Tol ID, Yousif M, Collins SL. Post traumatic stress disorder (PTSD): the psychological sequelae of abnormally invasive placenta (AIP). Placenta 2019; 81: 42-45
  • 56 Grover B, Einerson BD, Keenan KD. et al. Patient-reported health outcomes and quality of life after peripartum hysterectomy for placenta accreta spectrum. Am J Perinatol 2022; 39 (03) 281-287